期刊
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
卷 49, 期 3, 页码 1060-1073出版社
KARGER
DOI: 10.1159/000493286
关键词
Fgf18; Breast cancer; EMT; Akt/GSK3 beta/beta-catenin
资金
- National Natural Science Foundation of China [81602132, 81702891]
- Department of Science and Technology of Henan Province [182102310242, 172102310584, 172102310651]
- Education Department of Henan Province [201610472017, 201610472040]
- Doctoral Scientific Research Foundation of Xinxiang Medical University [XYBSKYZZ201512, 201513]
- Zhejiang Provincial Natural Science Foundation [LQ13H280002]
Background/Aims: Fibroblast growth factors (FGFs) and their high-affinity receptors contribute to autocrine and paracrine growth stimulation in several human malignant tumors, including breast cancer. However, the mechanisms underlying the carcinogenic actions of FGF18 remain unclear. Methods: The transcription level of FGF18 under the hypoxic condition was detected with quantitative PCR (qPCR). A wound-healing assay was performed to assess the role of FGF18 in cell migration. A clonogenicity assay was used to determine whether FGF18 silencing affected cell clonogenicity. Western blotting was performed to investigate Akt/GSK3 beta/beta-catenin pathway protein expression. Binding of beta-catenin to the target gene promoter was determined by chromatin immunoprecipitation (ChIP) assays. Results: FGF18 promoted the epithelial-mesenchymal transition (EMT) and migration in breast cancer cells through activation of the Akt/GSK3 beta/beta-catenin pathway. FGF18 increased Akt-Ser473 and -Thr308 phosphorylation, as well as that of GSK3 beta-Ser9. FGF18 also enhanced the transcription of proliferation-related genes (CDK2, CCND2, Ki67), metastasis-related genes (TGF-beta, MMP-2, MMP-9), and EMT markers (Snail-1, Snail-2, N-cadherin, vimentin, TIMP1). beta-catenin bound to the target gene promoter on the ChIP assay. Conclusion: FGF18 contributes to the migration and EMT of breast cancer cells following activation of the Akt/GSK3 beta/beta-catenin pathway. FGF18 expression may be a potential prognostic therapeutic marker for breast cancer. (C) 2018 The Author(s) Published by S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据